Cytokinetics Inc.
$69.39
$0.08 (+0.12%)
$68.67Day Range$70.68
Key Statistics
Market Cap
$9.64B
Shares Outstanding
139.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 29, 2004
Round Lot
100
Locale
US
Trading Data
Day Open
$69.52
Day High
$70.68
Day Low
$68.67
Volume
2.21M
VWAP
$69.51
Prev Close
$69.31
Transactions
--
Acc. Volume
--
About Cytokinetics Inc.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
PHARMACEUTICAL PREPARATIONSSIC 2834673 employees350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080(650) 624-3000IPO Apr 29, 2004US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001061983
- Composite FIGI
- BBG000F0R4N9
- Share Class FIGI
- BBG001SGMVF2
- Ticker Root
- CYTK
- SIC Code
- 2834
About Cytokinetics Inc. (CYTK) Stock
Cytokinetics Inc. (CYTK) closed the 2026-09-16 session at $69.39, up 0.12% versus the previous close (+0.08). The stock opened at $69.52 and traded between $68.67 and $70.68 during that session. Session trading volume was 2.2M shares. The volume-weighted average price (VWAP) is $69.51.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Cytokinetics Inc. has a market capitalization of $9.64 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CYTK is listed on the XNAS exchange. The company employs approximately 673 people. Cytokinetics Inc. is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2004-04-29.
On this page you can find market CYTK stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.